Tech Company Financing Transactions
Aktis Oncology Funding Round
Aktis Oncology, based in Princeton, secured $72 million in funding from EcoR1 Capital Management, MPM Capital and Vida Ventures.
Transaction Overview
Company Name
Announced On
3/19/2021
Transaction Type
Venture Equity
Amount
$72,000,000
Round
Series A
Investors
EcoR1 Capital Management (Lead Investor)
MPM Capital (Lead Investor) (Todd Foley)
Vida Ventures (Lead Investor)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Princeton, NJ 08540
USA
Princeton, NJ 08540
USA
Phone
Undisclosed
Website
Email Address
Overview
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Todd Foley
Chief Executive Officer
Matthew Roden
Browse more venture capital transactions:
Prev: 3/19/2021: Shelf Engine venture capital transaction
Next: 3/19/2021: Cylera venture capital transaction
Share this article
News on VC Transactions
We report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs